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Arthritis (RA) group with a clinical classification category of CCC 202. They were
matched with an equal number of respondents without RA as controls in order to
minimize the sample selection bias, using Greedy Match Propensity Score Match-
ing. Pre-disposing, enabling and need variables were matched using Chi-square
tests for categorical variables and t-tests for continuous variables in SAS, version 9.
Health-related quality of life instruments usedwere the Physical Component Sum-
mary (PCS-12) and the Mental Component Summary (MCS-12) of the SF-12 Health
Survey and the EuroQol 5D index. T-tests in STATA (R) were used to measures
group differences. RESULTS: Patients were statiscally matched on nine of ten vari-
ables. Themean (SE) PCS-12 scores for the RA and Non-RA groups were 34.25 (1.03)
and 45.46 (1.07). The mean (SE) MCS-12 scores for the RA and Non-RA groups were
47.50 (1.01) and 51.14 (0.83). The mean (SE) EQ-5D index scores for the RA and
Non-RA groups were 0.74 (0.02) and 0.86 (0.01). All lower scores were significant at
an a priori alpha value of 0.05. CONCLUSIONS: Lower scores on all measures indi-
cate that non- institutionalized adultswith self-reported RheumatoidArthritis (RA)
have a significantly lower health-realated quality of life.
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Fibromyalgia syndrome (FMS) is amulti-symptomdisorder primarily characterizedby
pain. In addition to pain, other symptoms include fatigue, irritable bowel disorder,
psychological disturbances like anxiety, depression, cognitive dysfunction etc. The
ambiguity of the symptoms and their overlapping naturewith other rheumatic disor-
ders poses a huge problem in diagnosis. Meanwhile, patient’s quality of life (QoL) is
compromised and deteriorates further. Hence, a thorough exploration in a clinical
setting is necessary. Generic instruments lack specificity,while the burgeoning symp-
tomspecific instruments present great respondent burden. Validated disease-specific
instruments seem to offer the best medium for complete evaluation of FMS patients.
OBJECTIVES: To identify available validated disease-specific instruments to enable
a comprehensive evaluation of fibromyalgia patients in a clinical setting.The ojec-
tive of this review is to provide clinicians and researchers with summarized infor-
mation on the available instruments and aid them in diagnosis of this disorder.
METHODS: A comprehensive literature review from January 1990 to June 2011 was
conducted with the combination of following key words fibromyalgia, disease-
specific, questionnaires, instruments etc. 58 articles that dealt with disease-spe-
cific instruments in FMS were identified of which 9 articles were included in the
final review. RESULTS: Only nine disease-specific instruments were identified in
literature which can be classified as: a) Diagnostic tools (2 instruments); b) QoL
evaluation tools (6 instruments); and c) Disease knowledge assessment tools (1
instrument). Most instruments possess strong psychometric properties that have
been tested in fibromyalgia patients. This review describes the instruments with
respect to their psychometric properties, strengths, and limitations.
CONCLUSIONS:These instruments can serve as supplementary aids to researchers
and clinicians for screening, evaluating, and monitoring FMS patients.
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OBJECTIVES:Telemedicine is considered a potentially efficient and effectiveway to
provide physical exercise therapy. To foster uptake of telemedicine exercise ser-
vices and to improve treatment compliance, it is important that services address
patients’ needs and preferences. Therefore, this study examines patients’ prefer-
ences of different telemedicine exercise services using a conjoint experiment.
METHODS: Implemented as part of a larger survey, preferences were estimated
using a choice-based conjoint experiment, spanning six relevant attributes of tele-
medicine exercise services. Attributes were indentified by means of qualitative
interviews and an expert focus group and included a) exercise mode and location;
b) presence of monitoring and feedback technology; c) counseling type; d) counsel-
ing frequency; e) flexibility of exercise hours; and f) willingness to accept as ex-
pressed in terms of a reduction in healthcare insurance premiums. Each patient
was presented with 15 choice tasks, consisting of two exercise service profiles and
an opt-out scenario. A bivariate probit regression analysis was used to estimate
preferences. RESULTS: Hundred and three patients were included in the analysis
after checking for patients’ understanding of the questionnaire using a dominant
option validity check. Themost important attribute levels were individual exercise
at gym, the use of monitoring and feedback technology, 100% face-to-face coun-
seling, counseling every session, flexible exercise hours and 45% health care insur-
ance reduction. Assistive telemedicine was preferred the most, over conventional
treatment and home-based telemedicine. Home-based telemedicinewas preferred
the least and ahealth care insurance reduction of 181 eurowould increase its utility
to the level of conventional treatment. CONCLUSIONS: Results show that patient-
centered telemedicine exercise services should integrate feedback andmonitoring
technology during treatment and emphasize the importance of supplementary
face-to-face counseling sessions. Offering health care insurance reduction could be
a way to further foster uptake of these future telemedicine services.
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OBJECTIVES: Rheumatoid arthritis (RA) is an incapacitating disease with prevalence
estimates ranging from 0.5% to 1% in Brazil, which demands early diagnose and ade-
quate treatment to slow down it’s progression. This study is aimed to assess co-mor-
bidity, quality of life (QoL), work/productivity loss, andmedical resource utilization in
patients diagnosed with RA in Brazil.METHODS: A total of 12,000 individuals’ (age
18) self-reported data were collected from 2011 National Health and Wellness
Survey (NHWS) in Brazil, a cross-sectional representative sample of the adult pop-
ulation. QOL was measured by the physical component score (PCS) and mental
component score (MCS) of the Short Form-12 (SF-12). Loss ofwork/productivitywas
measured by the validatedWork Productivity andActivity Impairment instrument.
Medical resource utilization was measured by health care provider utilization,
emergency room visits and hospitalization in the past 6 months. RESULTS: Of the
12,000 respondents, 65 (0.5%) had been diagnosed with RA, fromwhich 58.0% were
female. 45% of RA diagnosed group reported RA related problems once a month or
less, 27% say their problems occur daily, and 28% experience problems more often
than once per month, but not daily. On average, RA patients have been diagnosed
for 14 years. RA diagnosed group was more likely to suffer from the co-morbidities
of pain (59% vs.23%) and fibromyalgia (11%v s.1%), was more likely to visit an
emergency room in the past 6 months (41% vs.21%), presented lower mean PCS
scores (40% vs. 50%) and had higher percentages of absenteeism (9.2% vs.6.5%),
presenteeism (43.3% vs 14.5%)., work productivity loss (47%vs.18.5%) and activity
impairment (46.9% vs.20.3%) when compared to the group not diagnosed with RA.
All mentioned differences were statistically significant (p0.05). CONCLUSIONS:
Based on results from the Brazil NHWS, patients diagnosed with RA suffer from
impairment in QOL, work/productivity loss and more co-morbidities. Findings in-
dicate there is still an unmet medical need in RA patients in Brazil.
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OBJECTIVES: Poor nutrition, low dietary calcium intake, vitamin D deficiency, in-
sufficient exercise, smoking and alcohol usage aremodifiable risk factors that directly
affect bones and are associated with osteoporosis. In Brazil, there are no solid esti-
mates of the magnitude of the condition, due to being a country with a very hetero-
geneous racial, cultural and economic background. This study is aimed to assess co-
morbidity, quality of life (QOL), work/productivity loss, and medical resource
utilization in women with osteoporosis in Brazil. METHODS: A total of 12,000 indi-
viduals’ (age 18) self-reported data were collected from 2011 National Health and
Wellness Survey (NHWS) in Brazil. QOL was measured by the physical component
score (PCS) andmental component score (MCS) of the Short Form-12 (SF-12). Loss of
work/productivity was measured by the validated Work Productivity and Activity
Impairment instrument. Medical resource utilizationwasmeasured by health care
provider, emergency room visits and hospitalization in the past six months.
RESULTS: Of the 6017 female respondents, 179 (3.0%) were diagnosed with osteopo-
rosis (withorwithoutosteopenia) and156 (1.8%)werediagnosedwithosteopeniaonly.
Average age forwomendiagnosedwith osteoporosis/osteopeniawas 59.6 years. Diag-
nosed osteoporosis/osteopenia group reported more co-morbidities (headache 44%,
pain 36%, insomnia 26%, migraine 23%, depression 22%, arthritis 22%), lower mean
scores of PCS (42.6 vs.47.33) and MCS (45.7 vs. 50.3), more patients visited healthcare
providers (93%vs. 79%), and a higher percentage were using any cost-saving strategy
(55%vs. 37%)over thepast 6months compared tonon-osteoporosis/osteopeniagroup.
Furthermore, osteoporosis/osteopenia group reported 35.8% impairment in daily ac-
tivity compared to 23.0% innon-osteoporosis/osteopenia group.All comparisonswere
statistically significant at p 0.05. CONCLUSIONS: Based on results from the Brazil
NHWS, women diagnosed with osteoporosis/osteopenia suffer from impairment in
QOL,work/productivity loss, greater usage of health care resources andmore co-mor-
bidities. Findings indicate there is still an unmet medical need in osteoporosis/os-
teopenia patients in Brazil.
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OBJECTIVES: To measure the quality of life (QOL) in ankylosing sporidylitis (AS)
patients treated with Infliximab in China. METHODS: Patients’ self-reported data
were collected from a longitudinal survey which was conducted between June 10,
2009 and October 18, 2011 in AS patients at 40 urban hospitals in 23 cities in China.
QOL wasmeasured by Short Form-12 (SF-12) and each follow-up visit up to 8 visits.
RESULTS: Of the 609 survey respondents, 13.0% were treated with Infliximab (ex-
perienced-Infliximab group (EIG)) at baseline and follow ups, while 87.0% were not
treated with Infliximab at baseline but went on Infliximab treatment at the follow
ups (new-Infliximab group (NIG)). These two groups had no significant difference
with respect to age, gender and duration. Comparing with those in the NIG at
A44 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
baseline, patients in the EIG reported higher mean scores of physical component
(PCS) (42.7 vs. 35.8) and mental component (MCS) (47.5 vs. 43.0), as well as physical
functioning (48.4 vs. 42.6), role physical (39.0 vs. 30.9), bodily pain (45.2 vs. 38.2),
general health (36.9 vs. 31.4), vitality (52.5 vs. 47.6), social functioning (37.4 vs. 33.0),
role emotional (45.8 vs. 38.7) and mental health (52.8 vs. 46.9). All differences be-
tween the two groups were statistically significant at p 0.05. After 14 weeks of
Infliximab treatment, PCS andMCShad statistically significant improvements (10.7
and 9.8 respectively) from the baseline in the NIG, as well as all sub-domains of
SF-12; in the EIG, there were significant improvements in PCS (8.1), general health
(10.2) and mental health (4.1) from the baseline. CONCLUSIONS: The QOL was
significantly better for patients who received Infliximab therapy than for those not
treated with Infliximab. Infliximab initiating treatment and maintenance therapy
both help improve patients QOL. The results indicate that Infliximab improves the
quality of life of AS patients in China.
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OBJECTIVES: To assess the impact of Rheumatoid Arthritis (RA) and its treatment
on health- related quality of life (HRQOL) of RA patients and identify factors pre-
dicting the risk of disability and their poor Quality of Life (QOL). METHODS: A
observational cross-sectional study was carried out prospectively on 159 RA pa-
tients admitted in a tertiary care hospital. An interview questionnaire was used to
collect data. Patients’ medical records were reviewed. For evaluating the quality of
life and to assess functional disability in RA patients PROMIS-HAQ questionnaires
were used. To measure the disease activity in patients with RA Disease Activity
Score (DAS28) were used. Other outcome measures of disease activity were also
used. RESULTS:Mean age at time of admission was 47.8312.5SD years and 69.5%
of patients were having rheumatoid factor positive. About 82.2% patients had ac-
tive RA. The Mean scores  SDs on composite DAS28-ESR score was 4.9  0.4
reflectingmoderate disease activity andMeanHAQ-DI scorewas 2.30.3 indicating
much functional impairment. The HRQOL of all the patients was significantly
(p0.05) impairedwith a visual analogue scale equal to 56.7. Patientswith active RA
had poorer scores than patients in remission. Patient’s age, age at onset, disease
duration, patient’s assessment of pain were significantly (p0.05) associated with
disease severity and functional impairment. Moreover, disease activity and func-
tional disability measures were strongly associated with HRQOL measures. DAS28
score and family history of RA were the strongest predicators for functional im-
pairment. HAQ-DI score was the only significant predictor for QOL of RA patients.
CONCLUSIONS: HRQOL is an important measure in the regular assessment of the
disease. Present study showed a significant increase in HAQ scores as the physical
disability increased and a highly significant association between the DAS 28, as
well as the HAQ scores of patients with active RA.
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OBJECTIVES: To assess the quality of life (QOL) in rheumatoid arthritis (RA) pa-
tients treated with Infliximab in China.METHODS: A longitudinal survey was con-
ducted between June 10, 2009 and October 20, 2011 in RA patients at 37 urban
hospitals in 21 cities in China. Only respondents who reported with QOL (N363)
were included in this analysis. QOL was measured by Short Form-12 (SF-12) and
each follow-up visit up to 8 visits. RESULTS:Of the survey respondents, 12.7%were
treated with Infliximab (experienced-Infliximab group(EIG)) at baseline and follow
ups, while 87.3% were not treated with Infliximab at baseline but went on Inflix-
imab treatment at the follow ups (new-Infliximab group(NIG)). There were no sig-
nificant differences in age and gender between the two groups. Comparing with
those in the NIG at baseline, patients in the EIG reported higher mean physical
component score (PCS) (38.0 vs. 31.5) and mental component score (MCS) (46.8 vs.
38.3), as well as scores of physical functioning (44.9 vs. 36.6), role physical (34.3 vs.
26.2), bodily pain (41.3 vs. 33.5), general health (34.6 vs. 28.1), vitality (50.0 vs. 43.9),
social functioning (38.6 vs. 25.2), role emotional (40.1 vs. 34.6) and mental health
(50.0 vs. 43.2). All differences between the two groups were statistically significant
(p0.05). After 14 weeks Infliximab treatment, there were significant improve-
ments in PCS (12.2) and MCS (11.1) as well as all sub-domains of SF-12 from the
baseline in the NIG; in the EIG, there were significant improvements in PCS (10.1),
physical functioning (6.14) and general health (7.7) from the baseline.
CONCLUSIONS:RApatients treatedwith Infliximabhave better QOL than those not
treated with Infliximab. Continuing or initiating treatment with Infliximab im-
proves patients QOL. The findings indicate that Infliximab improves the quality of
life of RA patients in China.
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OBJECTIVES: The objective is to investigate changes of QOL, pain, and relevant
factors for Japanese osteoporosis female patients on onceweekly bisphosphonates
(BP) treatment. METHODS: A total of 6003 Japanese female osteoporosis patients
(55 years old and over) on BP treatment were enrolled at 308 study centers between
November 1, 2009 and April 30, 2011 and are being followed for two years. Medical
record review and patient survey are being conducted at the time of enrollment
(M0) as well as 3 (M3), 6 (M6), 12, and 24months after enrollment. We are collecting
information on patient background (e.g., age, concurrent diseases, pharmacother-
apy), QOL scores (Japanese Osteoporosis Quality of Life Questionnaire (JOQOL),
EQ-5D), and pain scores (Visual Analogue Scale (VAS), McGill Pain Questionnaire
(MPQ, Japanese version)). Interim analysis was conducted on data collected from
4,938 patients for M0, 3,375 patients for M3, and 2,465 patients for M6. RESULTS:
The average age was 73.3 (55-100) years old among the 4,938 patients, with 78.6 %
having concurrent diseases (e.g., hypertension, diabetes, osteoarthritis). Regarding
QOL, the total JOQOL scores of M0, M3, and M6 were 65.1, 66.7, and 67.3, respec-
tively, and the M3 and M6 scores were significantly increased in comparison with
M0 (p0.001). EQ-5D utility scores and EQ VAS of M3 andM6were also significantly
higher than M0 (p0.001). With regard to pain, VAS scores at M3 and M6 were
significantly improved from M0 (p0.001) and MPQ scores of M3 and M6 also indi-
cated relief of pain significantly from M0 (p0.01 and p0.001, respectively).
CONCLUSIONS: Improvement in QOL and pain scores of Japanese osteoporosis
patients on BP treatment for 6 months was observed consistently in all indicators
used.
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OBJECTIVES: Perform the measurement of quality of life related to health in pa-
tients with rheumatoid arthritis in Colombia, who are receiving biological therapy.
METHODS: In 252 patients with rheumatoid arthritis receiving biologic therapy, in
December 2010 to May 2011 - established the quality of life reported by the patient
by applying the Health Assessment Questionnaire (HAQ), and its correlation with
the level of disease activity scale as disease Activity Score (DAS28). The analysis
was supplemented by linear regression of HAQ variable depending on other vari-
ables of interest: DAS28, population characteristics, time of use, treatment received
and adverse events (AE). RESULTS: Linear regression showed that three variables
(DAS28 and adverse events) are significant in explaining variations in the quality of
life of patients with RA treated with biological therapy in Colombia. We found that
63,3% of patients with a DAS283.2 have less of one point in the HAQ score, while
in patients with DAS28 3.2, the 71.97% exceeded the HAQ score limit in one point.
The AE is and important variable in determining the quality of life of patients,
although on average only 15.6% of patients with RA showed AE regardless of bio-
logical treatment used. There were no significant differences by treatment type,
age and gender on the population studied. CONCLUSIONS:Quality of life related to
health (HAQ level) varies significantly depending on the state of disease activity
(DAS28) in patients treated with biological therapy.
PMS66
SATISFACTION WITH AND PREFERENCE FOR GOLIMUMAB AND ITS AUTO-
INJECTOR AMONG RHEUMATOID ARTHRITIS PATIENTS SWITCHED FROM
ADALIMUMAB OR ETANERCEPT
Tandon N1, Bolce R2, Naim A1, Bolge S1, Ellis L1, Piech CT1, Decktor D2
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Janssen Services, LLC, Horsham, PA, USA
OBJECTIVES: To evaluate patient satisfaction with golimumab (GLM) and its auto-
injector in rheumatoid arthritis (RA) patients switched from adalimumab (ADA) or
etanercept (ETA) due to inadequate disease control.METHODS: Data were from an
interim analysis of 200 patients enrolled in GO-SAVE, a GLMmulticenter, assessor-
blinded, switch study of patients with active RA. Patients receiving methotrexate
and having an inadequate response to current treatment with ADA or ETA entered
the screening period at week -6 and continued current treatment. After re-screen-
ing at week 0, all eligible patients were actively switched to open-label GLM 50mg
subcutaneous injections. Satisfaction prior to switching was assessed at week -2
for ADAorweek -1 for ETA. Satisfactionwith and preference for GLMwere assessed
at week 8. RESULTS:Mean (SD) age was 55.9 (11.3) years; 81.5% were female. Mean
(SD) disease duration was 9.8 (9.7) years. Prior to switch, patients were treated with
ADApen (25.5%), ADAprefilled syringe (21.5%), ETA pen (27%), ETA prefilled syringe
(24%), and ETA vial and syringe (2.0%). All 200 patients completed assessment at
week -2 (ADA) or -1 (ETA); 170 completed the assessment at week 8 (GLM). At week
8, 82.9% were satisfied with the overall GLM experience, 80.0% were satisfied with
injection frequency, and 75.3% were satisfied with injection device. Most patients
experienced lower levels of injection related burning (80.0%), stinging (75.3%), dis-
comfort (62.4%), redness (58.8%), and pain (57.6%) with the GLM auto-injector than
with the previous injection device. Patients expressed greater preference for GLM
over their previousmedication (74.0%) and greater preference for the auto-injector
(70.6%) over their previous injection device. CONCLUSIONS: A majority of RA pa-
tients switched to GLM from ADA or ETA were satisfied with their overall GLM
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